Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Nuclear Medicine Review
MENU
Shortcuts Submit an article Author Guidelines Editorial Board Reviewers 2023

open access

Vol 26 (2023): Continuous Publishing
Review paper
Submitted: 2022-12-06
Accepted: 2023-04-25
Published online: 2023-07-11
View PDF Download PDF file View HTML
Get Citation

Diagnosis and treatment of lung cancer using nuclear medicine techniques — current state of the art

Paulina Cegla1, Agnieszka Bos-Liedke2, Ewa Burchardt34, Ewelina Konstanty5, Adam Piotrowski2, Maciej Kozak2, Witold Cholewinski13
DOI: 10.5603/NMR.2023.0010
·
Nucl. Med. Rev 2023;26:77-84.
Affiliations
  1. Department of Nuclear Medicine, Greater Poland Cancer Center, Poznan, Poland
  2. Department of Biomedical Physics, Adam Mickiewicz University, Poznan, Poland
  3. Department of Electroradiology, Poznan University of Medical Science, Poznan, Poland
  4. Department of Radiotherapy and Gynaecological Oncology, Greater Poland Cancer Centre, Poznan, Poland
  5. Department of Medical Physics, Greater Poland Cancer Centre, Poznan, Poland

open access

Vol 26 (2023): Continuous Publishing
Reviews
Submitted: 2022-12-06
Accepted: 2023-04-25
Published online: 2023-07-11

Abstract

Lung cancer is the leading cause of cancer-related death worldwide. Planar radiography and computed tomography are the most common imaging modalities used in diagnosis, staging, and therapy response assessment. However, the role of nuclear methods in assessing the severity of the disease and the effectiveness of treatment has increased in recent years. Introducing these diagnostic modalities into standard practice in lung cancer may contribute to the personalization of treatment. In this review, we summarize the current knowledge of nuclear medicine techniques in the diagnosis and treatment of lung cancer.

Abstract

Lung cancer is the leading cause of cancer-related death worldwide. Planar radiography and computed tomography are the most common imaging modalities used in diagnosis, staging, and therapy response assessment. However, the role of nuclear methods in assessing the severity of the disease and the effectiveness of treatment has increased in recent years. Introducing these diagnostic modalities into standard practice in lung cancer may contribute to the personalization of treatment. In this review, we summarize the current knowledge of nuclear medicine techniques in the diagnosis and treatment of lung cancer.

Full Text:

View PDF Download PDF file View HTML
Get Citation

Keywords

lung cancer; positron emission tomography/computed tomography; single photon emission tomography/ /computed tomography; nuclear medicine; theragnostic

About this article
Title

Diagnosis and treatment of lung cancer using nuclear medicine techniques — current state of the art

Journal

Nuclear Medicine Review

Issue

Vol 26 (2023): Continuous Publishing

Article type

Review paper

Pages

77-84

Published online

2023-07-11

Page views

1489

Article views/downloads

511

DOI

10.5603/NMR.2023.0010

Bibliographic record

Nucl. Med. Rev 2023;26:77-84.

Keywords

lung cancer
positron emission tomography/computed tomography
single photon emission tomography/ /computed tomography
nuclear medicine
theragnostic

Authors

Paulina Cegla
Agnieszka Bos-Liedke
Ewa Burchardt
Ewelina Konstanty
Adam Piotrowski
Maciej Kozak
Witold Cholewinski

References (70)
  1. Gillman JA, Pantel AR, Mankoff DA, et al. Update on quantitative imaging for predicting and assessing response in oncology. Semin Nucl Med. 2020; 50(6): 505–517.
    CrossRefPubMed
  2. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6): 394–424.
    CrossRefPubMed
  3. Krzakowski M, Jassem J, Antczak A, et al. Cancer of the lung, pleura and mediastinum. Oncol Clin Pract. 2019; 15(1): 20–50.
    CrossRef
  4. Wang YXJ, Lo GG, Yuan J, et al. Magnetic resonance imaging for lung cancer screen. J Thorac Dis. 2014; 6(9): 1340–1348.
    CrossRefPubMed
  5. Uusijärvi H, Bernhardt P, Ericsson T, et al. Dosimetric characterization of radionuclides for systemic tumor therapy: influence of particle range, photon emission, and subcellular distribution. Med Phys. 2006; 33(9): 3260–3269.
    CrossRefPubMed
  6. Elliyanti A. An introduction to nuclear medicine in oncological molecular imaging. AIP Conference Proceedings. 2019.
    CrossRef
  7. Derlin T, Grünwald V, Steinbach J, et al. Molecular imaging in oncology using positron emission tomography. Dtsch Arztebl Int. 2018; 115(11): 175–181.
    CrossRefPubMed
  8. Bury T, Corhay JL, Duysinx B, et al. Value of FDG-PET in detecting residual or recurrent nonsmall cell lung cancer. Eur Respir J. 1999; 14(6): 1376–1380.
    CrossRefPubMed
  9. Machtay M, Duan F, Siegel BA, et al. Prediction of survival by [18F]fluorodeoxyglucose positron emission tomography in patients with locally advanced non-small-cell lung cancer undergoing definitive chemoradiation therapy: results of the ACRIN 6668/RTOG 0235 trial. J Clin Oncol. 2013; 31(30): 3823–3830.
    CrossRefPubMed
  10. Vera P, Mezzani-Saillard S, Edet-Sanson A, et al. FDG PET during radiochemotherapy is predictive of outcome at 1 year in non-small-cell lung cancer patients: a prospective multicentre study (RTEP2). Eur J Nucl Med Mol Imaging. 2014; 41(6): 1057–1065.
    CrossRefPubMed
  11. Rivera MP, Mehta AC, Wahidi MM. Establishing the diagnosis of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013; 143(5 Suppl): e142S–e165S.
    CrossRefPubMed
  12. Cho J, Kim S, Choe JG, et al. Delayed F-18 FDG uptake in PET distinguishes between TB and lung cancer: Determination of the optimal cut-off level using ROC analysis. J Nucl Med. 2016; 57(Supplement 2): 1469.
  13. Theodoropoulos AS, Gkiozos I, Kontopyrgias G, et al. Modern radiopharmaceuticals for lung cancer imaging with positron emission tomography/computed tomography scan: A systematic review. SAGE Open Med. 2020; 8.
    CrossRefPubMed
  14. Kaira K, Oriuchi N, Otani Y, et al. Fluorine-18-alpha-methyltyrosine positron emission tomography for diagnosis and staging of lung cancer: a clinicopathologic study. Clin Cancer Res. 2007; 13(21): 6369–6378.
    CrossRefPubMed
  15. Jager PL, Groen HJ, et al. van der Leest A, L-3-[123I]iodo-alpha-methyl-tyrosine SPECT in non-small cell lung cancer: preliminary observations. J Nucl Med. 2001; 42: 579–585.
  16. Akhoundova D, Hiltbrunner S, Mader C, et al. 18F-FET PET for diagnosis of pseudoprogression of brain metastases in patients with non-small cell lung cancer. Clin Nucl Med. 2020; 45(2): 113–117.
    CrossRefPubMed
  17. Hassanein M, Hight MR, Buck JR, et al. Preclinical evaluation of 4-[18f]fluoroglutamine PET to assess ASCT2 expression in lung cancer. Mol Imaging Biol. 2016; 18(1): 18–23.
    CrossRefPubMed
  18. Wang Hl, Wang Ss, Song Wh, et al. Expression of prostate-specific membrane antigen in lung cancer cells and tumor neovasculature endothelial cells and its clinical significance. PLoS One. 2015; 10(5): e0125924.
    CrossRefPubMed
  19. Bajc M, Neilly JB, Miniati M, et al. EANM Committee. EANM guidelines for ventilation/perfusion scintigraphy : Part 1. Pulmonary imaging with ventilation/perfusion single photon emission tomography. Eur J Nucl Med Mol Imaging. 2009; 36(8): 1356–1370.
    CrossRefPubMed
  20. Chirindel A, Cachovan M, Hans Vija A, et al. 3D-Quantitated lung perfusion 99mTc-MAA SPECT/CT: Impact on intended management in comparison to planar (2D) lung perfusion scan in lung cancer patients. J Nucl Me. 2019; 60(supplement 1).
  21. Genseke P, Wetz C, Wallbaum T, et al. Pre-operative quantification of pulmonary function using hybrid-SPECT/low-dose-CT: A pilot study. Lung Cancer. 2018; 118: 155–160.
    CrossRefPubMed
  22. Hirano T, Otake H, Yoshida I, et al. Primary lung cancer SPECT imaging with pentavalent technetium-99m-DMSA. J Nucl Med. 1995; 36(2): 202–207.
    PubMed
  23. Le Roux PY, Hicks RJ, Siva S, et al. PET/CT lung ventilation and perfusion scanning using galligas and gallium-68-maa. Semin Nucl Med. 2019; 49(1): 71–81.
    CrossRefPubMed
  24. Le Pennec R, Iravani A, Woon B, et al. Gallium-68 ventilation/perfusion PET-CT and CT pulmonary angiography for pulmonary embolism diagnosis: an interobserver agreement study. Front Med (Lausanne). 2020; 7: 599901.
    CrossRefPubMed
  25. Sachpekidis C, Thieke C, Askoxylakis V, et al. Combined use of (18)F-FDG and (18)F-FMISO in unresectable non-small cell lung cancer patients planned for radiotherapy: a dynamic PET/CT study. Am J Nucl Med Mol Imaging. 2015; 15(5): 127–142.
    PubMed
  26. Zegers C, Elmpt Wv, Wierts R, et al. Hypoxia imaging with [¹⁸F]HX4 PET in NSCLC patients: defining optimal imaging parameters. Radiother Oncol. 2013; 109(1): 58–64.
    CrossRef
  27. Kairemo K, Santos EB, Macapinlac HA, et al. Early response assessment to targeted therapy using 3'-deoxy-3'[(18)F]-fluorothymidine (F-FLT) PET/CT in lung cancer. Diagnostics (Basel). 2020; 10(1).
    CrossRefPubMed
  28. Alwadani B, Dall'Angelo S, Fleming IN. Clinical value of 3'-deoxy-3'-[F]fluorothymidine-positron emission tomography for diagnosis, staging and assessing therapy response in lung cancer. Insights Imaging. 2021; 12(1): 90.
    CrossRefPubMed
  29. Trigonis I, Koh PK, Taylor B, et al. Early reduction in tumour [18F]fluorothymidine (FLT) uptake in patients with non-small cell lung cancer (NSCLC) treated with radiotherapy alone. Eur J Nucl Med Mol Imaging. 2014; 41(4): 682–693.
    CrossRefPubMed
  30. Allen MD, Luong P, Hudson C, et al. Prognostic and therapeutic impact of argininosuccinate synthetase 1 control in bladder cancer as monitored longitudinally by PET imaging. Cancer Res. 2014; 74(3): 896–907.
    CrossRefPubMed
  31. Syed M, Flechsig P, Liermann J, et al. Fibroblast activation protein inhibitor (FAPI) PET for diagnostics and advanced targeted radiotherapy in head and neck cancers. Eur J Nucl Med Mol Imaging. 2020; 47(12): 2836–2845.
    CrossRefPubMed
  32. Kratochwil C, Flechsig P, Lindner T, et al. 68Ga-FAPI PET/CT: Tracer uptake in 28 different kinds of cancer. J Nucl Med. 2019; 60(6): 801–805.
    CrossRefPubMed
  33. Zhou Y, Gao S, Huang Y, et al. A pilot study of f-alfatide PET/CT imaging for detecting lymph node metastases in patients with non-small cell lung cancer. Sci Rep. 2017; 7(1): 2877.
    CrossRefPubMed
  34. Wei Y, Qin X, Luan X, et al. 18F-alfatide PET/CT may predict the survival of patients with stage II–IV lung cancer. J Nucl Med. 2020; 61: 1334.
  35. Kang F, Wang Z, Li G, et al. Inter-heterogeneity and intra-heterogeneity of αβ in non-small cell lung cancer and small cell lung cancer patients as revealed by Ga-RGD PET imaging. Eur J Nucl Med Mol Imaging. 2017; 44(9): 1520–1528.
    CrossRefPubMed
  36. Oxboel J, Schjoeth-Eskesen Ch, Madsen J, et al. Strong correlation between 64Cu-NODAGA-RGD uptake and quantitative gene expression of integrin-αVβ3 in human neuroendocrine tumor xenografts in mice. J Nucl Med. 2012; 53: 1101.
  37. Sanli Y, Garg I, Kandathil A, et al. Can complementary 68Ga-DOTATATE and 18F-FDG PET/CT establish the missing link between histopathology and therapeutic approach in gastroenteropancreatic neuroendocrine tumors? J Nucl Med. 2014; 55(11): 1811–1817.
    CrossRefPubMed
  38. Virgolini I, Ambrosini V, Bomanji JB, et al. Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging. 2010; 37(10): 2004–2010.
    CrossRefPubMed
  39. Kayani I, Conry BG, Groves AM, et al. A comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in pulmonary neuroendocrine tumors. J Nucl Med. 2009; 50(12): 1927–1932.
    CrossRefPubMed
  40. Vaccarili M, Lococo A, Fabiani F, et al. Clinical diagnostic application of 111In-DTPA-octreotide scintigraphy in small cell lung cancer. Tumori. 2000; 86(3): 224–228.
    CrossRefPubMed
  41. Khan AN, Al-Jahdali HH, Irion KL, et al. Solitary pulmonary nodule: A diagnostic algorithm in the light of current imaging technique. Avicenna J Med. 2011; 1(2): 39–51.
    CrossRefPubMed
  42. Blum J, Handmaker H, Lister-James J, et al. A multicenter trial with a somatostatin analog (99m)Tc depreotide in the evaluation of solitary pulmonary nodules. Chest. 2000; 117(5): 1232–1238.
    CrossRefPubMed
  43. Rezaeetalab F, Aryana K, Attaran D, et al. The role of octreotate scan in discrimination of solitary pulmonary nodule. World J Nucl Med. 2014; 13(1): 46–49.
    CrossRefPubMed
  44. Rashed HM, Marzook FA, Farag H. Tc-zolmitriptan: radiolabeling, molecular modeling, biodistribution and gamma scintigraphy as a hopeful radiopharmaceutical for lung nuclear imaging. Radiol Med. 2016; 121(12): 935–943.
    CrossRefPubMed
  45. Ehlerding EB, England CG, Majewski RL, et al. ImmunoPET imaging of CTLA-4 expression in mouse models of non-small cell lung cancer. Mol Pharm. 2017; 14(5): 1782–1789.
    CrossRefPubMed
  46. England CG, Jiang D, Ehlerding EB, et al. Zr-labeled nivolumab for imaging of T-cell infiltration in a humanized murine model of lung cancer. Eur J Nucl Med Mol Imaging. 2018; 45(1): 110–120.
    CrossRefPubMed
  47. Marcu LG. Imaging biomarkers of tumour proliferation and invasion for personalised lung cancer therapy. J Pers Med. 2020; 10(4).
    CrossRefPubMed
  48. Attili I, Tarantino P, Passaro A, et al. Strategies to overcome resistance to immune checkpoint blockade in lung cancer. Lung Cancer. 2021; 154: 151–160.
    CrossRefPubMed
  49. Takagi H, Zhao S, Muto S, et al. Delta-like 1 homolog (DLK1) as a possible therapeutic target and its application to radioimmunotherapy using I-labelled anti-DLK1 antibody in lung cancer models (HOT1801 and FIGHT004). Lung Cancer. 2021; 153: 134–142.
    CrossRefPubMed
  50. George GP, Pisaneschi F, Nguyen QD, et al. Positron emission tomographic imaging of CXCR4 in cancer: challenges and promises. Mol Imaging. 2014; 13.
    CrossRefPubMed
  51. De Silva RA, Peyre K, Pullambhatla M, et al. Imaging CXCR4 expression in human cancer xenografts: evaluation of monocyclam 64Cu-AMD3465. J Nucl Med. 2011; 52(6): 986–993.
    CrossRefPubMed
  52. Gourni E, Demmer O, Schottelius M, et al. PET of CXCR4 expression by a 68ga-labeled highly specific targeted contrast agent. J Nucl Med. 2011; 52(11): 1803–1810.
    CrossRef
  53. First in human and clinical studies – multi-organ physiology and metabolism. https://www.wmis.org/abstracts/2013/data/papers/SS112.html (24.03.2022).
  54. Sgouros G, Dewaraja YK, Escorcia F, et al. Tumor response to radiopharmaceutical therapies: the knowns and the unknowns. J Nucl Med. 2021; 62(Suppl 3): 12S–22S.
    CrossRefPubMed
  55. Govindan SV, Griffiths GL, Hansen HJ, et al. Cancer therapy with radiolabeled and drug/toxin-conjugated antibodies. Technol Cancer Res Treat. 2005; 4(4): 375–391.
    CrossRefPubMed
  56. Kramer-Marek G, Capala J. The role of nuclear medicine in modern therapy of cancer. Tumour Biol. 2012; 33(3): 629–640.
    CrossRefPubMed
  57. Dho SoH, Kim SY, Chung C, et al. Development of a radionuclide-labeled monoclonal anti-CD55 antibody with theranostic potential in pleural metastatic lung cancer. Sci Rep. 2018; 8(1): 8960.
    CrossRefPubMed
  58. Azad BB, Chatterjee S, Lesniak WG, et al. A fully human CXCR4 antibody demonstrates diagnostic utility and therapeutic efficacy in solid tumor xenografts. Oncotarget. 2016; 7(11): 12344–12358.
    CrossRefPubMed
  59. Pirooznia N, Abdi K, Beiki D, et al. Lu-labeled cyclic RGD peptide as an imaging and targeted radionuclide therapeutic agent in non-small cell lung cancer: Biological evaluation and preclinical study. Bioorg Chem. 2020; 102: 104100.
    CrossRefPubMed
  60. Pirooznia N, Abdi K, Beiki D, et al. Radiosynthesis, biological evaluation, and preclinical study of a 68ga-labeled cyclic RGD peptide as an early diagnostic agent for overexpressed α v β 3 integrin receptors in non-small-cell lung cancer. Contrast Media Mol Imaging. 2020: 8421657.
    CrossRefPubMed
  61. Zhao J, Zhou M, Li C. Synthetic nanoparticles for delivery of radioisotopes and radiosensitizers in cancer therapy. Cancer Nanotechnol. 2016; 7(1): 9.
    CrossRefPubMed
  62. Ming H, Fang L, Gao J, et al. Antitumor effect of nanoparticle 131I-labeled arginine-glycine-aspartate-bovine serum albumin-polycaprolactone in lung cancer. AJR Am J Roentgenol. 2017; 208(5): 1116–1126.
    CrossRefPubMed
  63. Chang CH, Chang MC, Chang YJ, et al. Translating research for the radiotheranostics of nanotargeted re-liposome. Int J Mol Sci. 2021; 22(8).
    CrossRefPubMed
  64. Lin LT, Chang CH, Yu HL, et al. Evaluation of the therapeutic and diagnostic effects of PEGylated liposome-embedded 188Re on human non-small cell lung cancer using an orthotopic small-animal model. J Nucl Med. 2014; 55(11): 1864–1870.
    CrossRefPubMed
  65. Chen P, Li J, Gui J, et al. Efficacy and safety of Re-HEDP in lung cancer patients with bone metastases: a randomized, multicenter, multiple-dose phase IIa study. Int J Clin Oncol. 2021; 26(7): 1212–1220.
    CrossRefPubMed
  66. Zhang H, Tian M, Li S, et al. Rhenium-188-HEDP therapy for the palliation of pain due to osseous metastases in lung cancer patients. Cancer Biother Radiopharm. 2003; 18(5): 719–726.
    CrossRefPubMed
  67. Levine R, Krenning EP. Clinical history of the theranostic radionuclide approach to neuroendocrine tumors and other types of cancer: historical review based on an interview of eric P. Krenning by rachel levine. J Nucl Med. 2017; 58(Suppl 2): 3S–9S.
    CrossRefPubMed
  68. Zidan L, Iravani A, Oleinikov K, et al. Efficacy and safety of 177Lu-DOTATATE in lung neuroendocrine tumors: a bicenter study. J Nucl Med. 2022; 63(2): 218–225.
    CrossRefPubMed
  69. Mariniello A, Bodei L, Tinelli C, et al. Long-term results of PRRT in advanced bronchopulmonary carcinoid. Eur J Nucl Med Mol Imaging. 2016; 43(3): 441–452.
    CrossRefPubMed
  70. Kim C, Liu S, Subramaniam D, et al. Phase I study of the 177Lu-DOTA0-Tyr3-Octreotate (lutathera) in combination with nivolumab in patients with neuroendocrine tumors of the lung. J Immunother Cancer. 2020; 8(2): e000980.
    CrossRef

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

phone: +48 58 320 94 94, fax: +48 58 320 94 60, e-mail: viamedica@viamedica.pl